The Effect of the Echinocandin Analogue Caspofungin on Cell Wall Glucan Synthesis by Cryptococcus neoformans
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The echinocandin derivative caspofungin (MK-0991, L-743,872) inhibits 1,3-beta-d-glucan synthesis and is active against several medically important fungi but is relatively ineffective against Cryptococcus neoformans. To investigate the mechanism of C. neoformans resistance, the prevalence of 1,3- and 1,6-beta-d-glucan linkages was determined in cells grown with and without caspofungin, using affinity-purified antisera and gold particle immunoelectron microscopy. Cryptococcal strains ATCC 24067 (serotype D) and MY2061 (serotype A) were studied. Growth at 4 microg/mL of caspofungin reduced both glucan linkages in both strains. However, growth at 2 microg/mL resulted in reduced 1,6-beta-d-glucan linkage only for MY2061. Inhibition of 1,6-beta-d-glucan synthesis may be an additional mechanism of action for pneumocandins. The relatively low efficacy of caspofungin against C. neoformans may result from reduced activity against C. neoformans glucan synthase or from yet undiscovered mechanisms of action operative in other fungal pathogens but not in C. neoformans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, J. R., Douglas, C. M., Li, W., Jue, C. K., Pramanik, B., Yuan, X., Rude, T. H., Toffaletti, D. L., Perfect, J. R., & Kurtz, M. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.2.444-453.1999 · Cited by 196 · cited 2×
“However, cryptococcal glucan synthase may be relatively resistant to the action of these drugs [6], resulting in the requirement for high concentrations to produce growth inhibition in vitro.”
Background
Cited by
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Limper, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
Regulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
“neoformans alone (56, 69, 99, 169), have exhibited positive interactions in combination with amphotericin B (71) or azoles (56, 71, 169), with some reports indicating indifference (169) and others indicating possible synergy (71).”
BackgroundAntifungal Resistance and New Strategies to Control Fungal Infections
Vandeputte, P., Ferrari, S., & Coste, A. T. (2012) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 505
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416
Impact of Melanin on Microbial Virulence and Clinical Resistance to Antimicrobial Compounds
Nosanchuk, J. D., & Casadevall, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00545-06 · Cited by 408
Self-citationEchinocandins: a new class of antifungal
Denning, D. W. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf045 · Cited by 300
Concepts and Principles of Photodynamic Therapy as an Alternative Antifungal Discovery Platform
Dai, T., Fuchs, B. B., Coleman, J. J., Prates, R. A., Astrakas, C., St. Denis, T. G., Ribeiro, M. S., Mylonakis, E., Hamblin, M. R., & Tegos, G. P. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00120 · Cited by 295
Saravolatz, L. D., Deresinski, S. C., & Stevens, D. A. (2003) · Clinical Infectious Diseases · doi:10.1086/375080 · Cited by 293
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
(2003) · PubMed · Cited by 240
Kraus, P. R., Fox, D. S., Cox, G. M., & Heitman, J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03508.x · Cited by 217
“…explanations have been proposed to explain the ineffectiveness of caspofungin against C. neoformans (Thompson et al., 1999; Del Poeta et al., 2000; Feldmesser et al., 2000). b-1,3-glucan is an essential component of the C. neoformans cell wall, but a reduction in b-1,3-glucan may be tolerable if…”
BackgroundResultAntifungal peptides: To be or not to be membrane active
Rautenbach, M., Troskie, A. M., & Vosloo, J. A. (2016) · Biochimie · doi:10.1016/j.biochi.2016.05.013 · Cited by 202
Stevens, D. A., Ichinomiya, M., Koshi, Y., & Horiuchi, H. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00563-06 · Cited by 193
“Our finding is consistent with suggestions from gene disruption studies (6) and studies of glucose linkages in Cryptococcus neoformans (7) and broadens our understanding of caspofungin antifungal mechanisms.”
ResultMaligie, M. A., & Selitrennikoff, C. P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2851-2856.2005 · Cited by 178
The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy
Wiederhold, N. P., & Lewis, R. E. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.8.1313 · Cited by 144
Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129
Caspofungin: first approved agent in a new class of antifungals
Johnson, M. D., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.807 · Cited by 85
“neoformans has less glucan in its cell wall, so echinocandins are relatively ineffective at clinically achievable dose [7].”
BackgroundInfluentialDistribution and impact of yeast thermal tolerance permissive for mammalian infection
Robert, V., Cardinali, G., & Casadevall, A. (2015) · BMC Biology · doi:10.1186/s12915-015-0127-3 · Cited by 79
Self-citationRecent Insights into the Paradoxical Effect of Echinocandins
Wagener, J., & Loiko, V. (2017) · Journal of Fungi · doi:10.3390/jof4010005 · Cited by 73
Loiko, V., & Wagener, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01690-16 · Cited by 51
Discovery of a Novel Antifungal Agent in the Pathogen Box
Mayer, F. L., & Kronstad, J. W. (2017) · mSphere · doi:10.1128/msphere.00120-17 · Cited by 49
Pianalto, K. M., Billmyre, R. B., Telzrow, C. L., & Alspaugh, J. A. (2019) · Genetics · doi:10.1534/genetics.119.302290 · Cited by 41
“Indeed, in Aspergillus fumigatus, cell wall chitin deposition, as well as the expression of chitin synthase genes, increases during caspofungin treatment (Fortwendel et al. 2009, 2010).”
Background
Metadata
- Authors
- Feldmesser, M., Kress, Y., Mednick, A., & Casadevall, A.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-12
- Volume
- 182
- Issue
- 6
- Pages
- 1791-1795
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2169230168
- Cited by
- 130
- References
- 1
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.